Ondansetron Stada (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Ondansetron Stada, is a 5‑HT3 receptor antagonist presented as a tablet for oral use. It is employed to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, and surgical procedures in adult patients. It is indicated for use in both inpatient and outpatient settings, improving patient comfort during intensive therapies.

GNH USA supplies Ondansetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting. - Chemotherapy-induced nausea and vomiting: reduces the frequency, intensity, and duration of nausea and vomiting in patients receiving moderately to highly emetogenic chemotherapy regimens. - Radiation-induced nausea and vomiting: prevents and controls nausea and vomiting that occur during or after abdominal, pelvic, or cranial radiotherapy, improving patient tolerance to treatment. - Postoperative nausea and vomiting: administered before surgery to help prevent nausea and vomiting during the postoperative recovery period, enhancing patient comfort and reducing the need for rescue antiemetics.

Ondansetron may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache that may be transient or persist during treatment. - Constipation: reduced bowel movements causing abdominal discomfort and the need for laxatives. - Diarrhoea: loose, watery stools that can lead to dehydration if severe. - Dizziness: sensation of light‑headedness or vertigo, especially when standing quickly.

Serious or Rare Side Effects: - QT interval prolongation: can cause abnormal heart rhythms, requiring ECG monitoring in at‑risk patients. - Severe allergic reaction: includes rash, itching, swelling of the face or throat, and possible anaphylaxis. - Serotonin syndrome: rare but potentially life‑threatening condition characterized by agitation, fever, muscle rigidity, and autonomic instability when combined with other serotonergic drugs. - Severe skin reactions: rare cases of Stevens‑Johnson syndrome or toxic epidermal necrolysis requiring immediate medical attention.

When prescribing Ondansetron, clinicians should consider several precautionary measures to ensure safe use. - Cardiac risk assessment: evaluate baseline ECG and electrolyte status in patients with known cardiac disease. - Concomitant QT‑prolonging drugs: avoid or monitor use with other medications that may lengthen the QT interval. - Hepatic impairment: adjust dosing or monitor closely in patients with severe liver dysfunction. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Renal impairment: consider dose modification in patients with significant renal insufficiency. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Apomorphine: concurrent use may cause severe hypotension and loss of consciousness. - Other 5‑HT3 antagonists: additive antiemetic effect can increase risk of QT prolongation. - Drugs that significantly prolong QT interval (e.g., quinidine, amiodarone, sotalol): may lead to dangerous cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may increase ondansetron plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce ondansetron effectiveness. - Opioids (e.g., fentanyl, morphine): may enhance the risk of constipation and sedation.